Ireland’s Janssen to be Branded as Johnson & Johnson

The company stated that these changes are part of a global rebranding initiative with the updated brand gradually being applied to all company materials, product packaging, and branding assets.

In a significant move, Johnson & Johnson’s Ireland-based pharmaceutical division has officially adopted its brand name.

Per the deal, the subsidiary Janssen will become Johnson & Johnson Innovative Medicine, and the medical technology segment will continue to be named Johnson & Johnson Medtech.

According to the company, the change marks the next era for Johnson & Johnson in Ireland.

The company stated that these changes are part of a global rebranding initiative announced in September 2023, with the updated brand gradually being applied to all company materials, product packaging, and branding assets.

Dana Daneshvari, VP, Manufacturing & GM, Large Molecule Manufacturing at Johnson & Johnson Innovative Medicine in Ringaskiddy, said that while the name and logo of the pharmaceutical segment of the business is changing, its goal remains the same.

"We innovate with purpose to lead where medicine is going, as we look to the future, we will continue to build on our legacy of innovation, delivering transformational medicines that improve patient outcomes and make a lasting impact on healthcare in Ireland," VP Daneshvari said.

This move aims to combat complex diseases with smarter, less invasive, and more personalized solutions.

The company's current R&D efforts are concentrated in oncology, immunology, neuroscience, cardiopulmonary, and specialty ophthalmology, aiming to transform the standard of care with personalized drug evaluations and therapeutic interventions for optimized clinical outcomes.

Operating in Ireland since 1935, Johnson & Johnson now employs over 6,000 people in the country.

Its Irish operations which comprise both the Innovative Medicine and Medtech segments, make a significant contribution to the company’s global success with ten sites located in five counties (Cork, Dublin, Limerick, Galway and Mayo) spanning R&D, manufacturing, shared services and country commercial businesses.

Johnson & Johnson’s Latest Advancements

In April, Johnson & Johnson entered into a definitive agreement with Shockwave to acquire all outstanding shares of the latter for $335.00 per share in cash, amounting to an enterprise value of approximately $13.1 billion, including cash acquired.

This transaction, approved by both companies' boards of directors, marks a strategic endeavor for Johnson & Johnson to expand its presence in cardiovascular intervention and tap into higher-growth markets.

The acquisition of Shockwave aligns with Johnson & Johnson's strategic focus on innovative medicine and medtech, particularly in addressing cardiovascular disease, which remains the leading cause of death globally.

Last year, Johnson & Johnson Vision, a global player in eye health, introduced the Silk (Smooth Incision Lenticule Keratomileusis) procedure in India.

The primary objective behind launching the Silk procedure is to empower surgeons with advanced technologies and designs that instill confidence in correcting refractive errors. This advancement also aims to enhance the overall surgical experience for patients while delivering positive outcomes.

Taking ahead the company's vision of going beyond ocular care, recently, Johnson & Johnson MedTech India partnered with Karkinos Healthcare. This collaboration sought to amalgamate digital learning methodologies with Karkinos' proficiency in establishing holistic cancer care systems within hospitals.